Research Article
An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis
Table 1
Baseline characteristics, clinical risk factors for thrombocytosis, and myeloid NGS result.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Age was determined at the time of NGS testing. Change in platelet count included a total of 75 patients (23 in the ET group and 52 in the secondary thrombocytosis group) with evaluable data and excludes any patients on cytoreductive therapy. Patients may have multiple secondary causes. Some patients may have multiple mutations (3 patients in the secondary thrombocytosis had multiple mutations and 25 patients in the ET group had a second mutation alongside their driver mutation). aMCV was calculated on the 159 patients not on any cytoreductive therapy at the time of NGS testing (17 patients were on hydroxyurea). BMI, body mass index; WBC, white blood cells; MCV, mean corpuscular volume; RDW, red cell distribution width; MPV, mean platelet volume; ANC, neutrophil count; JAK2, Janus Kinase 2 gene; CALR, Calreticulin gene; MPL, thrombopoietin receptor protein gene. |